Hero Image

Breakthrough in COPD: Monthly Biologic Injections and Who Qualifies

The biggest breakthrough in COPD in years is a new class of biologic injections, including one given once a month, for people who still have flare-ups on inhalers.

These newer therapies in COPD don't replace inhalers. They're added on top of them for a specific group of patients. This guide covers the latest approvals, COPD patient eligibility, how people pay, and how clinical trials and COPD research projects are shaping what comes next, including studies you can search for near you.

Recent Breakthroughs in COPD Treatment

For decades, COPD medicines focused on opening the airways. The newest treatments go after the inflammation that drives flare-ups.

Two biologics are now FDA-approved for adults with COPD and an eosinophilic phenotype. Eosinophils are white blood cells tied to airway inflammation, and a routine blood test shows whether your levels are raised.

Dupilumab (Dupixent) was approved for COPD in September 2024, making it the first biologic for the disease. It's injected under the skin every two weeks.

Mepolizumab (Nucala) was approved for COPD in May 2025. It's injected under the skin once every four weeks, which is where the "monthly injection" comes from.

Both are add-on maintenance treatments for adults whose COPD isn't well controlled on inhaled therapy. In clinical trials, adding either one reduced moderate and severe flare-ups compared with placebo.

There's also a newer non-biologic option. Ensifentrine (Ohtuvayre), approved in 2024, is a maintenance medicine taken through a nebulizer. It works differently from traditional inhalers and can be added to an existing regimen.

Can COPD Be Reversed?

It's a common question, and the honest answer matters. Lung damage from COPD can't be undone with current medicines, and none of these drugs is a cure.

What these newer therapies do is reduce flare-ups. That's a big deal, because flare-ups often lead to steroid bursts, antibiotics, hospital stays and faster decline. Fewer flare-ups means more stable days and a better shot at protecting the lung function you have.

How Monthly Biologic Injections Work

Biologics are made from living cells and designed to block one part of the immune response.

Mepolizumab targets interleukin-5 (IL-5), a signal that helps eosinophils grow and survive. Dupilumab blocks IL-4 and IL-13, two drivers of what's called type 2 inflammation.

Many patients learn to give the injection at home with a prefilled pen or syringe after training from their care team. Others receive it at a doctor's office.

Results build over time. Doctors usually judge the benefit over several months by tracking flare-ups, symptoms and breathing tests.

COPD Patient Eligibility: Who Qualifies?

Biologics are meant for a defined group of patients, not everyone with COPD. Doctors generally look for:

  • A confirmed diagnosis based on breathing tests (spirometry).
  • Ongoing flare-ups despite inhaled treatment. Most trial participants were already on triple therapy and still had exacerbations.
  • Raised blood eosinophils, measured with a simple blood count. The pivotal trials enrolled patients with elevated counts, commonly 300 cells per microliter or higher.
  • Documentation for insurance, such as records of recent flare-ups, lab results and proof that inhalers weren't enough.

If you've needed steroids, antibiotics or a hospital visit for COPD in the past year, ask your doctor about an eosinophil count. A pulmonologist can confirm whether you're a candidate.

Inhalers Still Come First

Biologics are added to inhalers, not used instead of them. Triple therapy combines an inhaled corticosteroid, a long-acting beta agonist and a long-acting muscarinic antagonist, often in a single inhaler.

Most people who qualify for a biologic are already on triple therapy or have tried it. Good inhaler technique and staying on schedule remain the foundation of care.

Paying for Newer COPD Therapies

Biologics carry high list prices, but most patients pay far less depending on their coverage.

Medicare: Self-injected biologics are usually covered under Part D, while those given in a clinic may be billed under Part B. Part D now has an annual out-of-pocket cap on covered drugs.

Private insurance: Prior authorization is standard. Manufacturer copay support can lower costs for many commercially insured patients, though it generally can't be combined with Medicare or Medicaid.

Medicaid: Coverage varies by state, and prior authorization is common.

Many specialty practices have staff who handle prior authorization and assistance paperwork. Ask your doctor's office who coordinates benefits.

COPD Research Projects and Clinical Trials

The next breakthrough in COPD is already in testing. Researchers are studying antibodies that target other inflammation pathways, including IL-33 and TSLP, with the goal of helping people who don't have high eosinophil counts.

Joining a COPD research project or clinical trial is one way to access investigational treatment, often with close monitoring from a specialist team. Trials have specific entry criteria, so expect screening tests before enrollment.

To find COPD clinical trials near you, ask your pulmonologist, check with academic medical centers in your area, and search the federal government's public clinical trials registry by condition and location.

Next Steps

If inhalers alone aren't keeping your flare-ups in check, you have more options than ever. Track your flare-ups, ask for a blood eosinophil test, and talk with a pulmonologist about whether a biologic or a research study fits your situation.